AFMD Affimed N.V.

-0.23  -8%
Previous Close 2.91
Open 2.9
Price To Book 3.44
Market Cap 167,312,684
Shares 62,430,106
Volume 1,843,862
Short Ratio
Av. Daily Volume 840,765

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b updated data at ICML June 22, 2019 noted ORR of 88% at highest dose, CR rates of 42%-46%.
AFM13 with Keytruda
Hodgkin Lymphoma - Cancer
Phase 2a ongoing.
Hodgkin Lymphoma - Cancer
Phase 1b/2a updated data at ICML June 19, 2019 noted 50% ORR.
CD30-positive lymphoma
Phase 1 program terminated - noted May 22, 2019.
Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)
Phase 2 trial to be initiated 2H 2019.
Relapsed/refractory peripheral T cell lymphoma (PTCL); transformed mycosis fungoides (TMF)

Latest News

  1. Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019
  2. The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
  3. Edited Transcript of AFMD earnings conference call or presentation 22-May-19 12:30pm GMT
  4. Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland
  5. Affimed Announces Annual General Meeting of Shareholders
  6. Icosagen and AbCheck Announce Five-year Licensing Agreement Granting AbCheck Access to Icosagen’s Patented Mammalian Expression Technology
  7. Affimed to Present at the Jefferies 2019 Healthcare Conference
  8. Affimed (AFMD) Earnings and Sales Exceed Estimates in Q1
  9. Affimed N.V. (AFMD) Q1 2019 Earnings Call Transcript
  10. Affirmed Therapeutics (AFMD) Beats Q1 Earnings and Revenue Estimates
  11. Affimed to end cancer program and focus on innate immunity portfolio, shares slide about 10%
  12. Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio; Reports First Quarter 2019 Financial Results and Operational Progress
  13. Affimed Q1 Earnings Preview
  14. Affimed Announces First Quarter 2019 Financial Results and Corporate Update Conference Call on May 22, 2019
  15. Affirmed Therapeutics (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
  16. What's in Store for Affimed (AFMD) This Earnings Season?
  17. Affirmed Therapeutics (AFMD) Moves to Buy: Rationale Behind the Upgrade
  18. If You Had Bought Affimed (NASDAQ:AFMD) Shares A Year Ago You'd Have Made 62%
  19. Affimed Provides Regulatory Update on AFM11 Clinical Program
  20. Implied Volatility Surging for Affimed (AFMD) Stock Options